Lin Yiting, Hu Chunyan, Wang Shuangyuan, Lin Hong
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Shanghai National Clinical Research Center for Endocrine and Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Metabolites. 2025 Jun 13;15(6):401. doi: 10.3390/metabo15060401.
Type 2 diabetes mellitus (T2DM), characterized by impaired glucose homeostasis, represents a significant threat to public health. Bile acids (BAs), as key metabolic regulators, play an essential role in glucose metabolism. Recent advances in high-resolution metabolomics have revealed that various BA species are closely linked to T2DM pathogenesis and play a critical role in maintaining glucose homeostasis. Understanding the underlying mechanisms by which BAs modulate glucose metabolism provides valuable insights for the prevention and treatment of T2DM.
METHODS/RESULTS: This review describes the roles of diverse BA species in regulating glucose metabolism and comprehensively summarizes the relationship of unconjugated and conjugated BAs with T2DM in population studies. Furthermore, we discuss BA-targeted therapeutic approaches for T2DM, highlighting the urgent need for developing tissue-restricted modulators of BA receptors and advancing the clinical translation of novel beneficial BAs.
Deeply understanding the role of BAs played in the pathogenesis and progression of T2DM will facilitate the development of potential therapeutic agents.
2型糖尿病(T2DM)以葡萄糖稳态受损为特征,对公众健康构成重大威胁。胆汁酸(BAs)作为关键的代谢调节因子,在葡萄糖代谢中起重要作用。高分辨率代谢组学的最新进展表明,各种胆汁酸种类与T2DM发病机制密切相关,并在维持葡萄糖稳态中起关键作用。了解胆汁酸调节葡萄糖代谢的潜在机制为T2DM的预防和治疗提供了有价值的见解。
方法/结果:本综述描述了不同胆汁酸种类在调节葡萄糖代谢中的作用,并全面总结了在人群研究中未结合和结合胆汁酸与T2DM的关系。此外,我们讨论了针对T2DM的胆汁酸靶向治疗方法,强调迫切需要开发组织限制性胆汁酸受体调节剂并推进新型有益胆汁酸的临床转化。
深入了解胆汁酸在T2DM发病机制和进展中的作用将有助于开发潜在的治疗药物。